Epidemiology, Risk Factors, Diagnosis and Treatment of Mucormycosis
(Black Fungus): A Review

Pragati      Upadhayay; Keshav      Bansal; Ahsas      Goyal
doi:10.2174/1389201024666230320111644
Abstract

The COVID-19 pandemic has shown an adverse effect worldwide, but in India, it has been observed during the second wave that people who recovered from COVID-19 infection developed a secondary infection because it grows in tandem with COVID-19 treatment. Meanwhile, news of a new deadly fungus has surfaced known as Mucormycosis (Black fungus). Mucormycosis is a fungal infection that invades the blood vessels and is caused by Mucormycetes, a group of fungi. Due to the post-pandemic effect of COVID-19 many fungal and bacterial diseases have affected the population. The reason behind the frequent development of opportunistic infections like mucormycosis is the use of steroids, oxygen masks, and antibiotics throughout the treatment of critically and severely ill patients with COVID-19. Inhaling filamentous fungi from the natural environment and a lack of supportive care units can be a risk factor for mucormycosis. It is usually found in people who are immunocompromised. Mucormycosis is more common in people with HIV/AIDS, COVID-19, congenital bone marrow disease, viral diseases, malignancies, severe burns, and irregularly or untreated and treated diabetes. This review emphasizes triggers that may precipitate mucormycosis related to corticosteroids, recent epidemiology, and incidence of mucormycosis. The infection was diagnosed and identified using a variety of cutting-edge medical techniques, including clinical diagnosis, histopathology, and serology. Many treatment methods, such as antifungal medications and therapies, have also been successfully used. The mortality rate, however, remains high due to an aggressive surgical excision or debridement and lack of early diagnosis.
« Previous Next »
Graphical Abstract

[1]
Wang, W.; Tang, J.; Wei, F. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. J. Med. Virol.,  2020, 92(4), 441-447.
 [http://dx.doi.org/10.1002/jmv.25689] [PMID:  31994742]

[2]
Frazier, K.M.; Hooper, J.E.; Mostafa, H.H.; Stewart, C.M. SARS-CoV-2 virus isolated from the mastoid and middle ear: Implications for COVID-19 precautions during ear surgery. JAMA Otolaryngol. Head Neck Surg.,  2020, 146(10), 964-966.
 [http://dx.doi.org/10.1001/jamaoto.2020.1922] [PMID:  32701126]

[3]
Chakrabarti, A.; Das, A.; Mandal, J.; Shivaprakash, M.R.; George, V.K.; Tarai, B.; Rao, P.; Panda, N.; Verma, S.C.; Sakhuja, V. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med. Mycol.,  2006, 44(4), 335-342.
 [http://dx.doi.org/10.1080/13693780500464930] [PMID:  16772227]

[4]
Lazar, S.P.; Lukaszewicz, J.M.; Persad, K.A.; Reinhardt, J.F. Rhinocerebral Mucor circinelloides infection in immunocompromised patient following yogurt ingestion. Del. Med. J.,  2014, 86(8), 245-248.
 [PMID:  25252436]

[5]
Lelievre, L.; Garcia-Hermoso, D.; Abdoul, H.; Hivelin, M.; Chouaki, T.; Toubas, D.; Mamez, A.C.; Lantieri, L.; Lortholary, O.; Lanternier, F. Posttraumatic mucormycosis. Medicine,  2014, 93(24), 395-404.
 [http://dx.doi.org/10.1097/MD.0000000000000221] [PMID:  25500709]

[6]
G Alshahawey, M.; S El-Housseiny, G.; S Elsayed, N.; Y Alshahrani, M.; Wakeel, L.M.E.L.; M Aboshanab, K. New insights on mucormycosis and its association with the COVID-19 pandemic. Future Sci. OA,  2022, 8(2), FSO772.
 [http://dx.doi.org/10.2144/fsoa-2021-0122] [PMID:  35059222]

[7]
Nasa, M.; Sharma, Z.; Lipi, L.; Sud, R. Gastric angioinvasive mucormycosis in immunocompetent adult, a rare occurrence. J. Assoc. Physicians India,  2017, 65(12), 103-104.
 [PMID:  29327534]

[8]
Nasir, N.; Farooqi, J.; Mahmood, S.F.; Jabeen, K. COVID‐19‐associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID‐19 pneumonia: An observational study from Pakistan. Mycoses,  2020, 63(8), 766-770.
 [http://dx.doi.org/10.1111/myc.13135] [PMID:  32585069]

[9]
News Live: Read Latest News, Headlines, Top News today, Breaking News Online. May 9, 2021.  Available from: https://economictimes.indiatimes.com/news?from=mdr

[10]
Panjabi, C.; Shah, A. Allergic Aspergillus sinusitis and its association with allergic bronchopulmonary aspergillosis. Asia Pac. Allergy,  2011, 1(3), 130-137.
 [http://dx.doi.org/10.5415/apallergy.2011.1.3.130] [PMID:  22053309]

[11]
Ferguson, B.J. Definitions of fungal rhinosinusitis. Otolaryngol. Clin. North Am.,  2000, 33(2), 227-235.
 [http://dx.doi.org/10.1016/S0030-6665(00)80002-X] [PMID:  10736401]

[12]
Chakrabarti, A.; Denning, D.W.; Ferguson, B.J.; Ponikau, J.; Buzina, W.; Kita, H.; Marple, B.; Panda, N.; Vlaminck, S.; Kauffmann-Lacroix, C.; Das, A.; Singh, P.; Taj-Aldeen, S.J.; Kantarcioglu, A.S.; Handa, K.K.; Gupta, A.; Thungabathra, M.; Shivaprakash, M.R.; Bal, A.; Fothergill, A.; Radotra, B.D. Fungal rhinosinusitis. Laryngoscope,  2009, 119(9), 1809-1818.
 [http://dx.doi.org/10.1002/lary.20520] [PMID:  19544383]

[13]
Gupta, J. Common respiratory viruses and collapsing health: Prodigious focus on ambient air pollution. Biomed. Biotechnol. Res. J.,  2022, 6(1), 7-13.
 [http://dx.doi.org/10.4103/bbrj.bbrj_201_21]

[14]
Baldin, C.; Ibrahim, A.S. Molecular mechanisms of mucormycosis-The bitter and the sweet. PLoS Pathog.,  2017, 13(8), e1006408.
 [http://dx.doi.org/10.1371/journal.ppat.1006408] [PMID:  28771587]

[15]
Mohindra, S.; Mohindra, S.; Gupta, R.; Bakshi, J.; Gupta, S.K. Rhinocerebral mucormycosis: The disease spectrum in 27 patients. Mycoses,  2007, 50(4), 290-296.
 [http://dx.doi.org/10.1111/j.1439-0507.2007.01364.x] [PMID:  17576322]

[16]
Harwansh, R.K.; Bahadur, S. Herbal medicines to fight against COVID-19: New battle with an old weapon. Curr. Pharm. Biotechnol.,  2022, 23(2), 235-260.
 [http://dx.doi.org/10.2174/1389201022666210322124348] [PMID:  33749558]

[17]
deShazo, R.D.; Chapin, K.; Swain, R.E. Fungal sinusitis. N. Engl. J. Med.,  1997, 337(4), 254-259.
 [http://dx.doi.org/10.1056/NEJM199707243370407] [PMID:  9227932]

[18]
Gillespie, M.B.; O’Malley, B.W. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol. Clin. North Am.,  2000, 33(2), 323-334.
 [http://dx.doi.org/10.1016/S0030-6665(00)80008-0] [PMID:  10736407]

[19]
González Ballester, D.; González-García, R.; Moreno, G.C.; Ruiz-Laza, L.; Monje, G.F. Mucormycosis of the head and neck: Report of five cases with different presentations. J. Craniomaxillofac. Surg.,  2012, 40(7), 584-591.
 [http://dx.doi.org/10.1016/j.jcms.2011.10.015] [PMID:  22082732]

[20]
Song, G.; Liang, G.; Liu, W. Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China. Mycopathologia,  2020, 185(4), 599-606.
 [http://dx.doi.org/10.1007/s11046-020-00462-9] [PMID:  32737747]

[21]
Gangneux, J.P.; Bougnoux, M.E.; Dannaoui, E.; Cornet, M.; Zahar, J.R. Invasive fungal diseases during COVID-19: We should be prepared. J. Mycol. Med.,  2020, 30(2), 100971.
 [http://dx.doi.org/10.1016/j.mycmed.2020.100971] [PMID:  32307254]

[22]
Biswas, S. Mucormycosis: The “black fungus” maiming COVID patients in India.  Available from: https://www.bbc.com/news/world-asia-india-57027829

[23]
Singh, A.K.; Singh, R.; Joshi, S.R.; Misra, A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab. Syndr.,  2021, 15(4), 102146.
 [http://dx.doi.org/10.1016/j.dsx.2021.05.019] [PMID:  34192610]

[24]
Rawson, T.M.; Moore, L.S.P.; Zhu, N.; Ranganathan, N.; Skolimowska, K.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and fungal coinfection in individuals with coronavirus: A Rapid review to support COVID-19 antimicrobial prescribing. Clin. Infect. Dis.,  2020, 71(9), ciaa530.
 [http://dx.doi.org/10.1093/cid/ciaa530] [PMID:  32358954]

[25]
Wagner, L.; de Hoog, S.; Alastruey-Izquierdo, A.; Voigt, K.; Kurzai, O.; Walther, G. A revised species concept for opportunistic Mucor species reveals species-specific antifungal susceptibility profiles. Antimicrob. Agents Chemother.,  2019, 63(8), e00653-e19.
 [http://dx.doi.org/10.1128/AAC.00653-19] [PMID:  31182532]

[26]
Walther, G.; Wagner, L.; Kurzai, O. Updates on the taxonomy of mucorales with an emphasis on clinically important taxa. J. Fungi,  2019, 5(4), 106.
 [http://dx.doi.org/10.3390/jof5040106] [PMID:  31739583]

[27]
Navanukroh, O.; Jitmuang, A.; Chayakulkeeree, M.; Ngamskulrungroj, P. Disseminated Cunninghamella bertholletiae infection with spinal epidural abscess in a kidney transplant patient: case report and literature review. Transpl. Infect. Dis.,  2014, 16(4), 658-665.
 [http://dx.doi.org/10.1111/tid.12251] [PMID:  24962170]

[28]
Dolatabadi, S.; Walther, G. Gerrits van den, E.A.H.G.; de Hoog, G.S. Diversity and delimitation of Rhizopus microsporus. Fungal Divers.,  2014, 64(1), 145-163.
 [http://dx.doi.org/10.1007/s13225-013-0229-6]

[29]
Alastruey-Izquierdo, A.; Hoffmann, K.; de Hoog, G.S.; Rodriguez-Tudela, J.L.; Voigt, K.; Bibashi, E.; Walther, G. Species recognition and clinical relevance of the zygomycetous genus Lichtheimia (syn. Absidia pro parte, Mycocladus). J. Clin. Microbiol.,  2010, 48(6), 2154-2170.
 [http://dx.doi.org/10.1128/JCM.01744-09] [PMID:  20357218]

[30]
Ribes, J.A.; Vanover-Sams, C.L.; Baker, D.J. Zygomycetes in human disease. Clin. Microbiol. Rev.,  2000, 13(2), 236-301.
 [http://dx.doi.org/10.1128/CMR.13.2.236] [PMID:  10756000]

[31]
DNA barcoding in Mucorales: an inventory of biodiversity: Ingenta Connect. 2022. Available from: https://www.ingentaconnect.com/content/nhn/pimj/2013/00000030/00000001/art00003 [Accessed: April 2 2022].

[32]
Bakathir, A.A. Mucormycosis of the jaw after dental extractions: Two case reports. Sultan Qaboos Univ. Med. J.,  2006, 6(2), 77-82.
 [PMID:  21748139]

[33]
Pillsbury, H.C.; Fischer, N.D. Rhinocerebral mucormycosis. Arch. Otolaryngol. Chic.,  1977, 103(10), 600-604.

[34]
Kumar, N.; Aggarwal, N.K. Global epidemiology of mucormycosis associated with post COVID-19 complication. Res. J. Biotechnol.,  2022, 17(3), 204-208.
 [http://dx.doi.org/10.25303/1703rjbt204208]

[35]
Sharma, M.C.; Gill, S.S.; Kashyap, S.; Kataria, R.; Gupta, D.K.; Sahni, P.; Acharya, S.K. Gastrointestinal mucormycosis-an uncommon isolated mucormycosis. Indian J. Gastroenterol.,  1998, 17(4), 131-133.
 [PMID:  9795498]

[36]
Spellberg, B. Gastrointestinal mucormycosis: An evolving disease. Gastroenterol. Hepatol.,  2012, 8(2), 140-142.
 [PMID:  22485085]

[37]
Kline, M.W. Mucormycosis in children: Review of the literature and report of cases. Pediatr. Infect. Dis. J.,  1985, 4(6), 672-676.
 [http://dx.doi.org/10.1097/00006454-198511000-00015] [PMID:  4080583]

[38]
Reimund, E.; Ramos, A. Disseminated neonatal gastrointestinal mucormycosis: A case report and review of the literature. Pediatr. Pathol.,  1994, 14(3), 385-389.
 [http://dx.doi.org/10.3109/15513819409024268] [PMID:  8065996]

[39]
Wani, A.A. Mucormycosis (Black Fungus) an emerging threat during 2nd wave of COVID-19 Pandemic in India: A review. Haya Saudi J. Life Sci.,  2021, 6(7), 143-146.
 [http://dx.doi.org/10.36348/sjls.2021.v06i07.003]

[40]
Straatsma, B.R.; Zimmerman, L.E.; Gass, J.D. Phycomycosis. A clinicopathologic study of fifty-one cases. Lab. Invest.,  1962, 11, 963-985.
 [PMID:  13984484]

[41]
Gleissner, B.; Schilling, A.; Anagnostopolous, I.; Siehl, I.; Thiel, E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk. Lymphoma,  2004, 45(7), 1351-1360.
 [http://dx.doi.org/10.1080/10428190310001653691] [PMID:  15359632]

[42]
Marr, K.A.; Carter, R.A.; Crippa, F.; Wald, A.; Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.,  2002, 34(7), 909-917.
 [http://dx.doi.org/10.1086/339202] [PMID:  11880955]

[43]
Morrison, V.A.; McGlave, P.B. Mucormycosis in the BMT population. Bone Marrow Transplant.,  1993, 11(5), 383-388.
 [PMID:  8504272]

[44]
Tedder, M.; Spratt, J.A.; Anstadt, M.P.; Hegde, S.S.; Tedder, S.D.; Lowe, J.E. Pulmonary mucormycosis: Results of medical and surgical therapy. Ann. Thorac. Surg.,  1994, 57(4), 1044-1050.
 [http://dx.doi.org/10.1016/0003-4975(94)90243-7] [PMID:  8166512]

[45]
Mead, J.H.; Lupton, G.P.; Dillavou, C.L.; Odom, R.B. Cutaneous Rhizopus infection. Occurrence as a postoperative complication associated with an elasticized adhesive dressing. JAMA,  1979, 242(3), 272-274.
 [http://dx.doi.org/10.1001/jama.1979.03300030044022] [PMID:  448920]

[46]
Gartenberg, G.; Bottone, E.J.; Keusch, G.T.; Weitzman, I. Hospital-acquired mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous tissue: Epidemiology, mycology and treatment. N. Engl. J. Med.,  1978, 299(20), 1115-1118.
 [http://dx.doi.org/10.1056/NEJM197811162992007] [PMID:  703789]

[47]
Sharma, A.; Goel, A. Mucormycosis: Risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol.,  2022, 67(3), 363-387.
 [http://dx.doi.org/10.1007/s12223-021-00934-5] [PMID:  35220559]

[48]
Mucormycosis (Zygomycosis): Background, etiology and pathophysiology, epidemiology.  Available from: https://emedicine.medscape.com/article/222551-overview [Accessed Aug 23 2021].

[49]
Ibrahim, A.S.; Spellberg, B.; Edwards, J., Jr Iron acquisition: A novel perspective on mucormycosis pathogenesis and treatment. Curr. Opin. Infect. Dis.,  2008, 21(6), 620-625.
 [http://dx.doi.org/10.1097/QCO.0b013e3283165fd1] [PMID:  18978530]

[50]
Nira, Kumar H. Epidemiological mucormycosis treatment and diagnosis challenges using the adaptive properties of computer vision techniques based approach: A review. Multimedia Tools Appl.,  2022, 81, 14217-14245.
 [http://dx.doi.org/10.1007/s11042-022-12450-w]

[51]
Elbossaty, W.F. The black fungus is one of the bad conse-quences of COVID 19. Clin. Onco.,  2021, 5(2), 1-4.

[52]
Sura, D.J. Explained: What are black, white and yellow fungal infections, why do they occur, and precautions to take.  Available from: https://www.outlookindia.com/website/story/india-news-explained-what-are-black-white-and-yellow-fungal-infections-why-do-they-occur-and-precautions-to-take/383950

[53]
Gupta, B.M.; Mamdapur, G.M.; Dayal, D. Black fungus (Mucormycosis) Research in India during 1998-2021: A scopus-based scientometric analysis. Int. J. Med. Public Health,  2021, 11(3), 133-138.
 [http://dx.doi.org/10.5530/ijmedph.2021.3.24]

[54]
Jeong, W.; Keighley, C.; Wolfe, R.; Lee, W.L.; Slavin, M.A.; Kong, D.C.M.; Chen, S.C.A. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin. Microbiol. Infect.,  2019, 25(1), 26-34.
 [http://dx.doi.org/10.1016/j.cmi.2018.07.011] [PMID:  30036666]

[55]
Bitar, D.; Lortholary, O.; Le Strat, Y.; Nicolau, J.; Coignard, B.; Tattevin, P.; Che, D.; Dromer, F. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg. Infect. Dis.,  2014, 20(7), 1163-1169.
 [http://dx.doi.org/10.3201/eid2007.140087] [PMID:  24960557]

[56]
Ambrosioni, J.; Bouchuiguir-Wafa, K.; Garbino, J. Emerging invasive zygomycosis in a tertiary care center: Epidemiology and associated risk factors. Int. J. Infect. Dis.,  2010, 14(S3), e100-e103.
 [http://dx.doi.org/10.1016/j.ijid.2009.11.024] [PMID:  20335060]

[57]
Guinea, J.; Escribano, P.; Vena, A.; Muñoz, P.; Martínez-Jiménez, M.C.; Padilla, B.; Bouza, E. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS One,  2017, 12(6), e0179136.
 [http://dx.doi.org/10.1371/journal.pone.0179136] [PMID:  28591186]

[58]
Park, B.J.; Pappas, P.G.; Wannemuehler, K.A.; Alexander, B.D.; Anaissie, E.J.; Andes, D.R.; Baddley, J.W.; Brown, J.M.; Brumble, L.M.; Freifeld, A.G.; Hadley, S.; Herwaldt, L.; Ito, J.I.; Kauffman, C.A.; Lyon, G.M.; Marr, K.A.; Morrison, V.A.; Papanicolaou, G.; Patterson, T.F.; Perl, T.M.; Schuster, M.G.; Walker, R.; Wingard, J.R.; Walsh, T.J.; Kontoyiannis, D.P. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg. Infect. Dis.,  2011, 17(10), 1855-1864.
 [http://dx.doi.org/10.3201/eid1710.110087] [PMID:  22000355]

[59]
Pagano, L.; Caira, M.; Nosari, A.; Van Lint, M.T.; Candoni, A.; Offidani, M.; Aloisi, T.; Irrera, G.; Bonini, A.; Picardi, M.; Caramatti, C.; Invernizzi, R.; Mattei, D.; Melillo, L.; de Waure, C.; Reddiconto, G.; Fianchi, L.; Valentini, C.G.; Girmenia, C.; Leone, G.; Aversa, F. Fungal infections in recipients of hematopoietic stem cell transplants: Results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis.,  2007, 45(9), 1161-1170.
 [http://dx.doi.org/10.1086/522189] [PMID:  17918077]

[60]
Lamoth, F.; Chung, S.J.; Damonti, L.; Alexander, B.D. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin. Infect. Dis.,  2017, 64(11), 1619-1621.
 [http://dx.doi.org/10.1093/cid/cix130] [PMID:  28199491]

[61]
Saegeman, V.; Maertens, J.; Meersseman, W.; Spriet, I.; Verbeken, E.; Lagrou, K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg. Infect. Dis.,  2010, 16(9), 1456-1458.
 [http://dx.doi.org/10.3201/eid1609.100276] [PMID:  20735932]

[62]
Webb, B.J.; Ferraro, J.P.; Rea, S.; Kaufusi, S.; Goodman, B.E.; Spalding, J. Epidemiology and clinical features of invasive fungal infection in a us health care network. Open Forum Infect. Dis.,  2018, 5(8), ofy187.
 [http://dx.doi.org/10.1093/ofid/ofy187] [PMID:  30151412]

[63]
Kontoyiannis, D.P.; Yang, H.; Song, J.; Kelkar, S.S.; Yang, X.; Azie, N.; Harrington, R.; Fan, A.; Lee, E.; Spalding, J.R. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: A retrospective study. BMC Infect. Dis.,  2016, 16(1), 730.
 [http://dx.doi.org/10.1186/s12879-016-2023-z] [PMID:  27905900]

[64]
Zilberberg, M.D.; Shorr, A.F.; Huang, H.; Chaudhari, P.; Paly, V.F.; Menzin, J. Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: A retrospective analysis of US hospital discharge data. BMC Infect. Dis.,  2014, 14(1), 310.
 [http://dx.doi.org/10.1186/1471-2334-14-310] [PMID:  24903188]

[65]
Kennedy, K.J.; Daveson, K.; Slavin, M.A.; van Hal, S.J.; Sorrell, T.C.; Lee, A.; Marriott, D.J.; Chapman, B.; Halliday, C.L.; Hajkowicz, K.; Athan, E.; Bak, N.; Cheong, E.; Heath, C.H.; Morrissey, C.O.; Kidd, S.; Beresford, R.; Blyth, C.; Korman, T.M.; Robinson, J.O.; Meyer, W.; Chen, S.C.A.; Clark, J.; McCormack, J.; Looke, D.; Playford, E.G.; Chen, S.; Gottlieb, T.; Halliday, C.; Marriott, D.; McMullan, B.; Meyer, W.; Sorrell, T.; van Hal, S.; Ananda-Rajah, M.; Morrissey, C.O.; Slavin, M.; Bak, N.; Kidd, S.; Arthur, I.; Blyth, C.; Heath, C.; Kennedy, K.; Daveson, K.; Morris, A.; Chambers, S. Mucormycosis in Australia: Contemporary epidemiology and outcomes. Clin. Microbiol. Infect.,  2016, 22(9), 775-781.
 [http://dx.doi.org/10.1016/j.cmi.2016.01.005] [PMID:  26806139]

[66]
Elgarten, C.W.; Levy, E.M.; Mattei, P.; Fisher, B.T.; Olson, T.S.; Freedman, J.L. Successful treatment of pulmonary mucormycosis in two pediatric hematopoietic stem cell transplant patients. Pediatr. Transplant.,  2018, 22(7), e13270.
 [http://dx.doi.org/10.1111/petr.13270] [PMID:  30014584]

[67]
Pana, Z.D.; Seidel, D.; Skiada, A.; Groll, A.H.; Petrikkos, G.; Cornely, O.A.; Roilides, E. Invasive mucormycosis in children: An epidemiologic study in European and non-European countries based on two registries. BMC Infect. Dis.,  2016, 16(1), 667.
 [http://dx.doi.org/10.1186/s12879-016-2005-1] [PMID:  27832748]

[68]
Manesh, A.; Rupali, P.; Sullivan, M.O.; Mohanraj, P.; Rupa, V.; George, B.; Michael, J.S. Mucormycosis-A clinicoepidemiological review of cases over 10 years – Manesh, 2019, 62(4), 391-398 - Mycoses. Wiley Online Library, 2019. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/myc.12897 [Accessed Mar 31 2022].

[69]
Patel, A.; Kaur, H.; Xess, I.; Michael, J.S.; Savio, J.; Rudramurthy, S.; Singh, R.; Shastri, P.; Umabala, P.; Sardana, R.; Kindo, A.; Capoor, M.R.; Mohan, S.; Muthu, V.; Agarwal, R.; Chakrabarti, A. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin. Microbiol. Infect.,  2020, 26(7), 944.e9-944.e15.
 [http://dx.doi.org/10.1016/j.cmi.2019.11.021] [PMID:  31811914]

[70]
Koffi, D.; Bonouman, I.V.; Toure, A.O.; Kouadjo, F.; N’Gou, M.R.E.; Sylla, K.; Dosso, M.; Denning, D.W. Estimates of serious fungal infection burden in Côte d’Ivoire and country health profile. J. Mycol. Med.,  2021, 31(1), 101086.
 [http://dx.doi.org/10.1016/j.mycmed.2020.101086] [PMID:  33259981]

[71]
Prakash, H.; Chakrabarti, A. Global epidemiology of mucormycosis. J. Fungi,  2019, 5(1), 26.
 [http://dx.doi.org/10.3390/jof5010026] [PMID:  30901907]

[72]
Prakash, H.; Chakrabarti, A. Epidemiology of mucormycosis in India. Microorganisms,  2021, 9(3), 523.
 [http://dx.doi.org/10.3390/microorganisms9030523] [PMID:  33806386]

[73]
Hanley, B.; Naresh, K.N.; Roufosse, C.; Nicholson, A.G.; Weir, J.; Cooke, G.S.; Thursz, M.; Manousou, P.; Corbett, R.; Goldin, R.; Al-Sarraj, S.; Abdolrasouli, A.; Swann, O.C.; Baillon, L.; Penn, R.; Barclay, W.S.; Viola, P.; Osborn, M. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: A post-mortem study. Lancet Microbe,  2020, 1(6), e245-e253.
 [http://dx.doi.org/10.1016/S2666-5247(20)30115-4] [PMID:  32844161]

[74]
Monte, Junior, E.S; Santos, M.E.L.; Ribeiro, I.B.; Luz, G.O.; Baba, E.R.; Hirsch, B.S.; Funari, M.P.; de Moura, E.G.H. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: A case report. Clin. Endosc.,  2020, 53(6), 746-749.
 [http://dx.doi.org/10.5946/ce.2020.180] [PMID:  33207116]

[75]
Pasero, D.; Sanna, S.; Liperi, C.; Piredda, D.; Branca, G.P.; Casadio, L.; Simeo, R.; Buselli, A.; Rizzo, D.; Bussu, F.; Rubino, S.; Terragni, P. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection,  2021, 49(5), 1055-1060.
 [http://dx.doi.org/10.1007/s15010-020-01561-x] [PMID:  33331988]

[76]
Chowdhary, A.; Tarai, B.; Singh, A.; Sharma, A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020. Emerg. Infect. Dis.,  2020, 26(11), 2694-2696.
 [http://dx.doi.org/10.3201/eid2611.203504] [PMID:  32852265]

[77]
White, P.L.; Dhillon, R.; Cordey, A.; Hughes, H.; Faggian, F.; Soni, S.; Pandey, M.; Whitaker, H.; May, A.; Morgan, M.; Wise, M.P.; Healy, B.; Blyth, I.; Price, J.S.; Vale, L.; Posso, R.; Kronda, J.; Blackwood, A.; Rafferty, H.; Moffitt, A.; Tsitsopoulou, A.; Gaur, S.; Holmes, T.; Backx, M. A national strategy to diagnose coronavirus disease 2019–associated invasive fungal disease in the intensive care unit. Clin. Infect. Dis.,  2021, 73(7), e1634-e1644.
 [http://dx.doi.org/10.1093/cid/ciaa1298] [PMID:  32860682]

[78]
Arastehfar, A.; Carvalho, A.; van de Veerdonk, F.L.; Jenks, J.D.; Koehler, P.; Krause, R.; Cornely, O.A.; S Perlin, D. Lass-Flörl, C.; Hoenigl, M. COVID-19 associated pulmonary aspergillosis (CAPA)-From immunology to treatment. J. Fungi,  2020, 6(2), 1-17.
 [http://dx.doi.org/10.3390/jof6020091] [PMID:  32599813]

[79]
Jethva, J.; Patel, R.; Bhagat, P.; Prajapati, V.; Thakkar, H.; Prajapati, K. Rhino-orbital-cerebral mucormycosis: An epidemiological study from a tertiary care referral center in Western India. Indian J. Ophthalmol.,  2022, 70(4), 1371-1375.
 [http://dx.doi.org/10.4103/ijo.IJO_2943_21] [PMID:  35326057]

[80]
Kumar, A.; Verma, M.; Hakim, A.; Sharma, S.; Meena, R.; Bhansali, S. Epidemiology of mucormycosis cases during the second wave of COVID-19 in a tertiary care institute in western Rajasthan, India. Cureus,  2022, 14(3), e22973.
 [http://dx.doi.org/10.7759/cureus.22973] [PMID:  35415040]

[81]
Joshi, S.; Telang, R.; Tambe, M.; Havaldar, R.; Sane, M.; Shaikh, A.; Roy, C.; Yathati, K.; Sonawale, S.; Borkar, R.; Magar, R.; Bhitkar, H.; Shitole, S.; Nakate, L.; Kudrimoti, J.; Mave, V. Outbreak of mucormycosis in coronavirus disease patients, Pune, India. Emerg. Infect. Dis.,  2022, 28(1), 1-8.
 [http://dx.doi.org/10.3201/eid2801.211636] [PMID:  34586055]

[82]
Mehta, S.; Pandey, A. Rhino-orbital mucormycosis associated with COVID-19. Cureus,  2020, 12(9), e10726.
 [PMID:  33145132]

[83]
Garg, D.; Muthu, V.; Sehgal, I.S.; Ramachandran, R.; Kaur, H.; Bhalla, A.; Puri, G.D.; Chakrabarti, A.; Agarwal, R. Coronavirus disease (Covid-19) Associated Mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia,  2021, 186(2), 289-298.
 [http://dx.doi.org/10.1007/s11046-021-00528-2] [PMID:  33544266]

[84]
Werthman-Ehrenreich, A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am. J. Emerg. Med.,  2021, 42, 264.e5-264.e8.
 [http://dx.doi.org/10.1016/j.ajem.2020.09.032] [PMID:  32972795]

[85]
Kanwar, A.; Jordan, A.; Olewiler, S.; Wehberg, K.; Cortes, M.; Jackson, B.R. A fatal case of Rhizopus azygosporus pneumonia following COVID-19. J. Fungi,  2021, 7(3), 174.
 [http://dx.doi.org/10.3390/jof7030174] [PMID:  33670842]

[86]
Karimi-Galougahi, M.; Arastou, S.; Haseli, S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID‐19). Int. Forum Allergy Rhinol.,  2021, 11(6), 1029-1030.
 [http://dx.doi.org/10.1002/alr.22785] [PMID:  33713565]

[87]
Veisi, A.; Bagheri, A.; Eshaghi, M.; Rikhtehgar, M.H.; Rezaei Kanavi, M.; Farjad, R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur. J. Ophthalmol.,  2021, 10, 1-6.
 [PMID:  33843287]

[88]
Pakdel, F.; Ahmadikia, K.; Salehi, M.; Tabari, A.; Jafari, R.; Mehrparvar, G.; Rezaie, Y.; Rajaeih, S.; Alijani, N.; Barac, A.; Abdollahi, A.; Khodavaisy, S. Mucormycosis in patients with COVID‐19: A cross‐sectionall descriptive multicentre study from Iran. Mycoses,  2021, 64(10), 1238-1252.
 [http://dx.doi.org/10.1111/myc.13334] [PMID:  34096653]

[89]
Sungurtekin, H.; Sargin, F.; Akbulut, M.; Karaduman, S. Severe rhinocerebralmucormycosis case developed after COVID-19. J. Bacteriol. Parasitol.,  2021, 12, 1-7.

[90]
Bellanger, A.P.; Navellou, J.C.; Lepiller, Q.; Brion, A.; Brunel, A.S.; Millon, L.; Berceanu, A. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infectious Diseases Now,  2021, 51(7), 633-635.
 [http://dx.doi.org/10.1016/j.idnow.2021.01.010] [PMID:  33527098]

[91]
Zurl, C.; Hoenigl, M.; Schulz, E.; Hatzl, S.; Gorkiewicz, G.; Krause, R.; Eller, P.; Prattes, J. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically Ill COVID-19 patient with underlying hematological malignancy. J. Fungi,  2021, 7(2), 88.
 [http://dx.doi.org/10.3390/jof7020088] [PMID:  33513875]

[92]
Waizel-Haiat, S.; Guerrero-Paz, J.A.; Sanchez-Hurtado, L.; Calleja-Alarcon, S.; Romero-Gutierrez, L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus,  2021, 13(2), e13163.
 [http://dx.doi.org/10.7759/cureus.13163] [PMID:  33575155]

[93]
Ibrahim, A.S. Host cell invasion in mucormycosis: Role of iron. Curr. Opin. Microbiol.,  2011, 14(4), 406-411.
 [http://dx.doi.org/10.1016/j.mib.2011.07.004] [PMID:  21807554]

[94]
Sharma, H.; Singh, S.; Pathak, S. Pathogenesis of COVID-19, disease outbreak: A review. Curr. Pharm. Biotechnol.,  2021, 22(12), 1591-1601.
 [http://dx.doi.org/10.2174/1389201022666210127113441] [PMID:  33504302]

[95]
Walsh, T.J.; Gamaletsou, M.N.; McGinnis, M.R.; Hayden, R.T.; Kontoyiannis, D.P. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin. Infect. Dis.,  2012, 54(S1), S55-S60.
 [http://dx.doi.org/10.1093/cid/cir868] [PMID:  22247446]

[96]
Chamilos, G.; Lewis, R.E.; Kontoyiannis, D.P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin. Infect. Dis.,  2008, 47(4), 503-509.
 [http://dx.doi.org/10.1086/590004] [PMID:  18611163]

[97]
Marty, F.M.; Cosimi, L.A.; Baden, L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med.,  2004, 350(9), 950-952.
 [http://dx.doi.org/10.1056/NEJM200402263500923] [PMID:  14985500]

[98]
Corzo-León, D.E.; Chora-Hernández, L.D.; Rodríguez-Zulueta, A.P.; Walsh, T.J. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med. Mycol.,  2018, 56(1), 29-43.
 [http://dx.doi.org/10.1093/mmy/myx017] [PMID:  28431008]

[99]
Petrikkos, G.; Skiada, A.; Lortholary, O.; Roilides, E.; Walsh, T.J.; Kontoyiannis, D.P. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis.,  2012, 54(S1), S23-S34.
 [http://dx.doi.org/10.1093/cid/cir866] [PMID:  22247442]

[100]
Chamilos, G.; Marom, E.M.; Lewis, R.E.; Lionakis, M.S.; Kontoyiannis, D.P. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin. Infect. Dis.,  2005, 41(1), 60-66.
 [http://dx.doi.org/10.1086/430710] [PMID:  15937764]

[101]
Jiménez-Zarazúa, O; Vélez-Ramírez, LN; Alcocer-León, M; Utrilla-Álvarez, JD; Martínez-Rivera, MA; Flores-Saldaña, GA Mondragón JD. A case of concomitant pulmonary tuberculosis and mucormycosis in an insulin-dependent diabetic patient. J. Clin. Tuberc. Other Mycobact. Dis.,  2019, 16, 100105.
 [http://dx.doi.org/10.1016/j.jctube.2019.100105] [PMID:  31720429]

[102]
Legouge, C.; Caillot, D.; Chrétien, M.L.; Lafon, I.; Ferrant, E.; Audia, S.; Pagès, P.B.; Roques, M.; Estivalet, L.; Martin, L.; Maitre, T.; Bastie, J.N.; Dalle, F. The reversed halo sign: Pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin. Infect. Dis.,  2014, 58(5), 672-678.
 [http://dx.doi.org/10.1093/cid/cit929] [PMID:  24352351]

[103]
Jung, J.; Kim, M.Y.; Lee, H.J.; Park, Y.S.; Lee, S.O.; Choi, S.H. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin. Microbiol. Infect.,  2015, 21(7), 684-e11-684-e18.
 [http://dx.doi.org/10.1016/j.cmi.2015.03.019]

[104]
Agrawal, R.; Yeldandi, A.; Savas, H.; Parekh, N.D.; Lombardi, P.J.; Hart, E.M. Pulmonary mucormycosis: Risk factors, radiologic findings, and pathologic correlation. Radiographics,  2020, 40(3), 656-666.
 [http://dx.doi.org/10.1148/rg.2020190156] [PMID:  32196429]

[105]
Skiada, A.; Pavleas, I.; Drogari-Apiranthitou, M. Epidemiology and diagnosis of mucormycosis: An update. J. Fungi,  2020, 6(4), 265.
 [http://dx.doi.org/10.3390/jof6040265] [PMID:  33147877]

[106]
Ribes, J.A.; Vanover-Sams, C.L; Baker, D.J. Zygomycetes in human disease. Clin. Microbiol. Rev.,  2000, 13(2), 236-301. Available from: https://journals.asm.org/doi/full/10.1128/CMR.13.2.236 [Accessed Apr 1 2022].

[107]
Sandven, P.; Eduard, W. Detection and quantitation of antibodies against Rhizopus by enzyme-linked immunosorbent assay. Acta Pathol. Microbiol. Scand. Suppl.,  1992, 100(7-12), 981-987.
 [http://dx.doi.org/10.1111/j.1699-0463.1992.tb04029.x] [PMID:  1472367]

[108]
Wysong, D.R.; Waldorf, A.R. Electrophoretic and immunoblot analyses of Rhizopus arrhizus antigens. J. Clin. Microbiol.,  1987, 25(2), 358-363.
 [http://dx.doi.org/10.1128/jcm.25.2.358-363.1987] [PMID:  3546367]

[109]
Jones, K.W.; Kaufman, L. Development and evaluation of an immunodiffusion test for diagnosis of systemic zygomycosis (mucormycosis): preliminary report. J. Clin. Microbiol.,  1978, 7(1), 97-101.
 [http://dx.doi.org/10.1128/jcm.7.1.97-101.1978] [PMID:  75212]

[110]
Potenza, L.; Vallerini, D.; Barozzi, P.; Riva, G.; Forghieri, F.; Zanetti, E.; Quadrelli, C.; Candoni, A.; Maertens, J.; Rossi, G.; Morselli, M.; Codeluppi, M.; Paolini, A.; Maccaferri, M.; Del Giovane, C.; D’Amico, R.; Rumpianesi, F.; Pecorari, M.; Cavalleri, F.; Marasca, R.; Narni, F.; Luppi, M. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood,  2011, 118(20), 5416-5419.
 [http://dx.doi.org/10.1182/blood-2011-07-366526] [PMID:  21931119]

[111]
Skiada, A.; Lass-Floerl, C.; Klimko, N.; Ibrahim, A.; Roilides, E.; Petrikkos, G. Challenges in the diagnosis and treatment of mucormycosis. Med. Mycol.,  2018, 56(S1), S93-S101.
 [http://dx.doi.org/10.1093/mmy/myx101] [PMID:  29538730]

[112]
Azhar, A.; Khan, W.H.; Khan, P.A.; Alhosaini, K.; Owais, M.; Ahmad, A. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach. J. Infect. Public Health,  2022, 15(4), 466-479.
 [http://dx.doi.org/10.1016/j.jiph.2022.02.007] [PMID:  35216920]

[113]
Atkinson, A.; Colburn, W.; Degruttola, V.; Demets, D.; Downing, G.J.; Hoth, D.F. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther.,  2001, 69(3), 89-95.
 [http://dx.doi.org/10.1067/mcp.2001.113989] [PMID:  11240971]

[114]
Lackner, M.; Caramalho, R.; Lass-Flörl, C. Laboratory diagnosis of mucormycosis: Current status and future perspectives. Future Microbiol.,  2014, 9(5), 683-695.
 [http://dx.doi.org/10.2217/fmb.14.23] [PMID:  24957094]

[115]
Samson, R.; Dharne, M. COVID-19 associated mucormycosis: Evolving technologies for early and rapid diagnosis. 3 Biotech.,  2022, 12(1), 1-7.
 [http://dx.doi.org/10.1007/s13205-021-03080-4] [PMID:  34900512]

[116]
Voigt, K.; Cigelnik, E.; O’donnell, K. Phylogeny and PCR identification of clinically important Zygomycetes based on nuclear ribosomal-DNA sequence data. J. Clin. Microbiol.,  1999, 37(12), 3957-3964.
 [http://dx.doi.org/10.1128/JCM.37.12.3957-3964.1999] [PMID:  10565914]

[117]
Scherer, E.; Iriart, X.; Bellanger, A.P.; Dupont, D.; Guitard, J.; Gabriel, F.; Cassaing, S.; Charpentier, E.; Guenounou, S.; Cornet, M.; Botterel, F.; Rocchi, S.; Berceanu, A.; Millon, L. Quantitative PCR (qPCR) detection of Mucorales DNA in bronchoalveolar lavage fluid to diagnose pulmonary mucormycosis. J. Clin. Microbiol.,  2018, 56(8), e00289-18.
 [http://dx.doi.org/10.1128/JCM.00289-18] [PMID:  29875192]

[118]
Ashkenazi-Hoffnung, L.; Bilavsky, E.; Avitzur, Y.; Amir, J. Successful treatment of cutaneous zygomycosis with intravenous amphotericin B followed by oral posaconazole in a multivisceral transplant recipient. Transplantation,  2010, 90(10), 1133-1135.
 [http://dx.doi.org/10.1097/TP.0b013e3181f86916] [PMID:  21427635]

[119]
Kyvernitakis, A.; Torres, H.A.; Jiang, Y.; Chamilos, G.; Lewis, R.E.; Kontoyiannis, D.P. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: A propensity score analysis. Clin. Microbiol. Infect.,  2016, 22(9), 811.e1-811.e8.
 [http://dx.doi.org/10.1016/j.cmi.2016.03.029] [PMID:  27085727]

[120]
Chatterjee, S.; Vardhan, B.; Singh, D.K.; Maitra, A.; Ojha, U.K. Should statins be considered for the management of mucormycosis in COVID-19? Diabetes Metab. Syndr.,  2021, 15(4), 102162.
 [http://dx.doi.org/10.1016/j.dsx.2021.05.035] [PMID:  34186353]

[121]
Thompson, G.R., III; Wiederhold, N.P. Isavuconazole: A comprehensive review of spectrum of activity of a new triazole. Mycopathologia,  2010, 170(5), 291-313.
 [http://dx.doi.org/10.1007/s11046-010-9324-3] [PMID:  20524153]

[122]
Arendrup, M.C.; Jensen, R.H.; Meletiadis, J. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order. Antimicrob. Agents Chemother.,  2015, 59(12), 7735-7742.
 [http://dx.doi.org/10.1128/AAC.01919-15] [PMID:  26438494]

[123]
Bullen, J.J.; Rogers, H.J.; Spalding, P.B.; Ward, C.G. Natural resistance, iron and infection: a challenge for clinical medicine. J. Med. Microbiol.,  2006, 55(3), 251-258.
 [http://dx.doi.org/10.1099/jmm.0.46386-0] [PMID:  16476787]

[124]
Scott, C.; Arora, G.; Dickson, K.; Lehmann, C. Iron chelation in local infection. Molecules,  2021, 26(1), 189.
 [http://dx.doi.org/10.3390/molecules26010189] [PMID:  33401708]

[125]
Roilides, E.; Lyman, C.A.; Panagopoulou, P.; Chanock, S. Immunomodulation of invasive fungal infections. Infect. Dis. Clin. North Am.,  2003, 17(1), 193-219.
 [http://dx.doi.org/10.1016/S0891-5520(02)00070-3] [PMID:  12751266]

[126]
Mahalmani, V.; Sarma, P.; Prakash, A.; Medhi, B. Role of iron chelators in mucormycosis. Indian J. Pharmacol.,  2021, 53(4), 261-263.
 [PMID:  34414902]

[127]
Mujwar, S.; Harwansh, R.K. In silico bioprospecting of taraxerol as a main protease inhibitor of SARS-CoV-2 to develop therapy against COVID-19. Struct. Chem.,  2022, 33(5), 1517-1528.
 [http://dx.doi.org/10.1007/s11224-022-01943-x] [PMID:  35502321]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1389201024666230320111644	Print ISSN 1389-2010
Publisher Name Bentham Science Publisher	Online ISSN 1873-4316
Current Pharmaceutical Biotechnology

Epidemiology, Risk Factors, Diagnosis and Treatment of Mucormycosis (Black Fungus): A Review

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract
